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Abstract
Background: Asthma heritability has only been partially explained by genetic variants and is known to be sensitive
to environmental factors, implicating epigenetic modifications such as DNA methylation in its pathogenesis.
Methods: Using data collected in the Avon Longitudinal Study of Parents and Children (ALSPAC), we assessed
associations of asthma and wheeze with DNA methylation at 7.5 and 16.5 years, at over 450,000 CpG sites in DNA
from the peripheral blood of approx. 1000 participants. We used Mendelian randomization (MR), a method of causal
inference that uses genetic variants as instrumental variables, to infer the direction of association between DNA
methylation and asthma.
Results: We identified 302 CpGs associated with current asthma status (FDR-adjusted P value < 0.05) and 445 with
current wheeze status at 7.5 years, with substantial overlap between the two. Genes annotated to the 302
associated CpGs were enriched for pathways related to movement of cellular/subcellular components, locomotion,
interleukin-4 production and eosinophil migration. All associations attenuated when adjusted for eosinophil and
neutrophil cell count estimates. At 16.5 years, two sites were associated with current asthma after adjustment for
cell counts. The CpGs mapped to the AP2A2 and IL5RA genes, with a − 2.32 [95% CI − 1.47, − 3.18] and − 2.49 [95%
CI − 1.56, − 3.43] difference in percentage methylation in asthma cases respectively.
Two-sample bi-directional MR indicated a causal effect of asthma on DNA methylation at several CpG sites at 7.
5 years. However, associations did not persist after adjustment for multiple testing. There was no evidence of a
causal effect of asthma on DNA methylation at either of the two CpG sites at 16.5 years.
Conclusion: The majority of observed associations are driven by higher eosinophil cell counts in asthma cases, acting
as an intermediate phenotype, with important implications for future studies of DNA methylation in atopic diseases.
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Background
Asthma continues to be a global burden on health care
systems with 8.2% of the US population affected in 2009
[1] and 300 million affected worldwide [2]. The preva-
lence of paediatric asthma in particular is on the rise
along with modern lifestyle factors such as air pollutants
and indoor contaminants and allergens thought to be
influencing the increase [3]. Although asthma is known
to be strongly heritable [4], genome-wide association
studies (GWAS) have only been able to explain a
fraction of that heritability [5, 6].
As asthma development and progression are affected
by environmental factors, a hypothesised role for epigen-
etic mechanisms has been proposed [7–9]. There has
been particular interest in a role for DNA methylation,
one of the most widely studied epigenetic mechanisms
which is known to be responsive to environmental expo-
sures [10]. DNA methylation variation has previously
been found to be associated with known asthma triggers,
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including air pollution [11, 12] and smoking [13, 14].
Whereas childhood asthma is often allergic in character
and is more common in boys than in girls [15, 16], adult
asthma is known to differ in that it is often more severe,
non-atopic and leads to a more rapid decline in lung
function [16], indicating different biological mechanisms
involved in the pathophysiology between asthma in
childhood and asthma in late adolescence.
Wheeze is a symptom often observed as a precursor
to children that develop asthma [17, 18] and has been
indicated to have important prognostic value in early de-
tection of asthma [19]. Whereas wheeze and asthma are
related traits, wheezing is a broader and more heteroge-
neous phenotype than asthma that encompasses a wider
variety of respiratory conditions, which may include dis-
orders such as chronic obstructive pulmonary disorder
(COPD), viral infection and bronchiolitis [20]. Associa-
tions of wheeze with DNA methylation may be expected
to capture a wider variety of biological processes that
underlie respiratory conditions.
Previous studies have reported an association between
peripheral blood DNA methylation and IgE [21, 22], an
important mediator of atopic or inflammatory diseases
such as asthma. However, whether these associations are
also present for the asthma phenotype has not been
assessed. Studies that have examined DNA methylation
associations with asthma have not specifically deter-
mined whether observed associations are due to cell type
confounding between samples [23, 24]. Eosinophils, a
type of circulating granulocyte, are known to be in-
creased in peripheral blood of some people with allergic
conditions, such as certain subtypes of asthma [25, 26].
Eosinophils are involved in the development of charac-
teristic features of asthma, such as airway remodelling
and hyperreponsiveness, heightened immune response
and initiation of allergic airway inflammation [27, 28].
The increase of eosinophils in some individuals with
asthma may lead to ‘confounding’ or contamination of
whole-blood methylation data [29, 30], as the distinct
methylation patterns of eosinophils [31] are over-
represented in cases.
Associations observed between DNA methylation and
disease outcomes, like all observational associations, are
vulnerable to confounding, reverse causation and bias.
Determining the direction of association is of critical im-
portance to the biological interpretation of such findings
[32]. The Mendelian randomization (MR) is an approach
that uses genetic variants as instrumental variables (IVs)
and has been widely implemented to strengthen causal
inference [33, 34]. Any association observed between the
IVs and the disease outcome is most likely explained by
an unbiased causal effect of the exposure on the out-
come, given a certain set of prior assumptions [34]. MR
can make use of the strong cis effects of genetic variants
on DNA methylation. Cis-genetic variants robustly asso-
ciated with site-specific DNA methylation can be identi-
fied and used as causal anchors in such analyses [21, 35].
This approach is particularly useful in the case of DNA
methylation, where the causal direction of association
between DNA methylation and the disease outcome may
be difficult to establish using observational data alone.
Furthermore, the application of MR is increasingly facili-
tated by the availability of GWAS data from large-scale
consortia as the methods can be applied using summary
level statistics [36].
In the present study, we examine genome-wide DNA
methylation in relation to asthma and wheeze in
childhood and adolescence in a large contemporary UK-
based cohort. We implement a variety of analytical strat-
egies to gain insights into causal relationships of the
DNA methylation variation observed.
Methods
Study population
The Avon Longitudinal Study of Parents and Children
(ALSPAC) recruited 14,541 pregnant women resident in
the former county of Avon, UK, with expected dates of de-
livery 1 April 1991 to 31 December 1992. The initial num-
ber of pregnancies was 14,541, for which the mother
enrolled in the ALSPAC study and had either returned at
least one questionnaire or attended a ‘Children in Focus’
clinic by 19 July 1999. Of these initial pregnancies, there
was a total of 14,062 live births and 13,988 children who
were alive at 1 year of age. The phases of enrolment are
described in detail in the cohort profile paper [37]. The
study website contains details of all the data that is avail-
able through a searchable data dictionary http://www.bri-
s.ac.uk/alspac/researchers/data-access/data-dictionary/.
Written informed consent has been obtained for all
ALSPAC participants. Ethical approval was granted from
the ALSPAC Law and Ethics Committee and the local Re-
search Ethics Committee in accordance with the guide-
lines of the Declaration of Helsinki.
Respiratory phenotypes
Estimates of current asthma/wheeze status and ever
asthma/wheeze were derived from questionnaires com-
pleted by the mothers of the study children when they
were 7.5 and 16.5 years old respectively. Current asthma
case status at 7.5 years of age was defined using a posi-
tive answer to the question ‘Has your child ever been di-
agnosed with asthma by a doctor?’ and a positive answer
to one of the following questions: (1) ‘Has your child
had asthma in the past 12 months?’ (2) ‘Has your child
been on asthma medication the last 12 months?’ or (3)
‘Has your study child had wheezing or whistling on the
chest in the past 12 months?’. Controls were children
with negative answers to all the above questions.
Arathimos et al. Clinical Epigenetics  (2017) 9:112 Page 2 of 16
Current wheeze at 7.5 years was defined using answers
to the question ‘Has your child had wheezing or whist-
ling on the chest in the last 12 months?’. Wheeze is a re-
spiratory condition that may capture broader respiratory
pathology that includes but is not limited to asthma.
However, not all asthmatics currently wheeze since
many are currently taking medication that supress dis-
ease symptoms. The number of individuals with current
asthma at 7.5 years is therefore larger than the number
of individuals with wheeze at that age due to this lack of
symptom manifestation in some asthmatics. Current
asthma case status at 16.5 years was defined using the
same method but from counterpart questions asked in
the child-completed questionnaire. Ever asthma and ever
wheeze at 16.5 years were defined using answers to the
questions from questionnaires completed at 16.5 years
of age by the mothers of the study participants. Answers
to the questions ‘Has he/she [your study child] ever had
asthma?’ and ‘Has he/she ever had wheezing or whistling
in the chest at any time in the past?’ were used to define
each measure respectively.
DNA methylation data
DNA methylation data for a subset of approximately
1000 mother-child pairs from ALSPAC is available as
part of the ARIES (Accessible Resource for Integrated
Epigenomics Studies) project [38]. ARIES participants
were selected based on availability of DNA samples at
three time-points for the offspring (neonatal, childhood
and adolescence). Mothers included in ARIES were
slightly older, more likely to have a non-manual occupa-
tion and less likely to have smoked throughout preg-
nancy when compared to the total ALSPAC study
cohort [38]. DNA methylation was measured using the
Illumina Infinium HumanMethylation450 BeadChip.
DNA methylation at each CpG site is expressed as a
beta-value (β) (ratio of methylated probe intensity to
overall intensity representing 0 to 100% methylation at
the CpG) based on the proportion of detected CpGs that
were methylated at each site on the array [39]. Pre-
processing of peripheral blood and cord blood samples
was performed as previously described [38]. Details of
quality control (QC) of the DNA methylation data can
be found in Additional file 1.
Other variables
Proportions of cell types were estimated from DNA
methylation data using the estimateCellCounts function in
the minfi R package [40] which is based on the method
developed by Houseman et al. [41]. This estimated the
proportion of B cells, CD8 T cells, CD4 T cells, granulo-
cytes, eosinophils, neutrophils, NK cells and monocytes at
the 7.5-year methylation time point and at the 16.5-year
methylation time-point independently. Descriptive statistics
of the derived cell counts can be seen in Additional file 1:
Table S1. All epigenome-wide association study (EWAS)
analyses were adjusted for three levels of cell-type adjust-
ment. Model 1: unadjusted for cells, model 2: basic cells
(where eosinophils and neutrophils were grouped together
as granulocytes) and model 3: detailed cells (eosinophils
and neutrophils assessed separately).
Atopic status was determined in a subset of ALSPAC
children when they were approximately 7.5 years old by
skin prick test response to a panel of up to 12 common al-
lergens, including house dust mite, grass pollen and cat.
Discrimination of atopic status based on house dust mite,
grass pollen and cat has been previously shown to identify
over 95% of sensitised children [42], and we were primar-
ily interested in allergic response to aeroallergens as indi-
cators of atopic status which have a plausible biological
link to respiratory conditions such as asthma. A positive
response was defined as a mean weal diameter of > 2 mm
with an absent response to negative control solution, and
atopy was defined as a positive response to one or more of
house dust mite, grass pollen and cat.
Statistical analyses
We first examined cross-sectional associations of asthma
status at both 7.5 and 16.5 years with estimated cell
counts. We used linear regression models in Stata 13
MP2 [43] to determine associations between cell types
that were most likely to have a strong effect on results
when adjusted for in EWAS models.
Epigenome-wide association studies
EWAS were carried out in R version 3.0.2. using the
CpGassoc package [44] to model either asthma/wheeze
status as the exposure and methylation (beta value) at ei-
ther 7.5 or 16.5 years of age as the outcome. In addition
to the cross-sectional EWAS, we also examined two lon-
gitudinal EWAS models of current asthma. We did this
in order to determine if the asthma status in childhood
was longitudinally associated with DNA methylation in
adolescence or if DNA methylation in childhood was
longitudinally associated with asthma status in adoles-
cence. We specified one model with DNA methylation
at 7.5 years (as the exposure) and later life current
asthma status at 16.5 years (as the outcome), and one
with current asthma at 7.5 years (as the exposure) and
DNA methylation at 16.5 years (as the outcome).
EWAS results were then corrected for multiple testing
by controlling the expected proportion of false-positives
among all discoveries (false discovery rate (FDR)-ad-
justed P value < 0.05), and type 1 errors were controlled
using Bonferroni adjustment. All models were adjusted
for sex, maternal smoking during pregnancy, maternal
age, parity, maternal education derived from maternal
questionnaires and unknown confounders using surrogate
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variables (by use of maximum 10 surrogate variables
obtained from the sva R package [45]), as shown in
Additional file 1: Table S2. Probes that were known to
contain SNPs or be of low quality [46] were removed. The
genomic inflation factor (lambda λ) and quantile-quantile
(Q-Q) plots were used to compare the genome-wide dis-
tribution of P values with the expected null distribution.
We examined three models: Model 1 was adjusted off-
spring sex, maternal age, parity, smoking status, mater-
nal education and for unknown confounders using
surrogate variables; model 2 adjusted additionally for
basic cell counts (which grouped eosinophils and neu-
trophils under granulocytes); and model 3 adjusted for
covariates as above and detailed cell counts. Longitu-
dinal EWAS models were adjusted for estimated cell
counts at the relevant DNA methylation time point.
Sensitivity analyses
We performed a sensitivity analysis where individuals with
extreme values of derived eosinophil cell counts at
7.5 years were removed using Tukey’s method of outlier
removal [47, 48]. This was done as some evidence suggest
eosinophilic asthma represents a subtype of asthma within
a wider spectrum of asthmatic disorders [49, 50]. We used
both a stringent and a relaxed version of Tukey’s method.
For the stringent method, potential outliers in the eosino-
phil cell count data were removed if their value was more
than the upper quartile plus one and a half times the inter-
quartile range (IQR). For the relaxed method, outliers
were removed if their value was more than the upper
quartile plus three times the IQR. We did not remove
values that were less than the lower quartile minus three
times the interquartile range as having an eosinophil cell
count of zero (or near-zero) is normal for most healthy in-
dividuals. We also stratified the outlier removal by sex to
determine whether outliers in eosinophil cell counts were
more frequent in females or males.
Functional analysis
The Gene Ontology (GO) [51] database in Database for
Annotation, Visualisation and Integrated Discovery
(DAVID) [52] Bioinformatics Resources 6.8 (beta) was
used to examine gene function in potential molecular,
cellular and biological processes of loci observed to be
associated with asthma at age 7.5 years (adjusted for
basic cell counts). The Kyoto Encyclopedia of Genes and
Genomes (KEGG) database [53] in DAVID was used to
explore whether genes were related to known pathways
involved in asthma or eosinophil regulation.
Mendelian randomization
In order to investigate the causal relationships between
DNA methylation and asthma, a MR approach was
applied. Briefly, MR is a method of investigating causal
relationships by using genetic variants as IVs [33]. The
principle of MR is based on Mendel’s laws of segregation
and independent assortment. Genetic variants that ad-
here to those laws are distributed independently and
randomly with respect to other genetic variants, assum-
ing no linkage disequilibrium (LD) or population stratifi-
cation. Randomization of these genetic variants ensures
that any association observed between the genetic vari-
ants and the outcome is most likely explained by an un-
biased causal effect of the exposure on the outcome.
The reasoning for this is that the MR design is analo-
gous to a randomized control trial (RCT), where study
participants are randomly allocated to one or another
treatment, avoiding potential confounding between
treatment and outcome. The MR approach relies on
three key assumptions: that the genetic variants cause
the exposure; that there is no path from genetic variants
to outcome other than via exposure (i.e. no pleiotropy);
and that the genetic variants are not associated with any
of the confounders of the exposure-outcome association
[54, 55]. A two-sample approach to MR was used which
has the additional benefit of only requiring summary
level data from an outcome GWAS and an exposure
GWAS. The strengths and limitations of this specific
technique have been reviewed [56, 57]. A bi-directional
approach was implemented in order to assess both the
potential causal effect of asthma on DNA methylation
and the effect of DNA methylation on asthma. The Two-
SampleMR package in R available as part of the MR-
Base (www.mrbase.org) platform [36] was used for all
MR analyses. We analysed the causal effect of the
asthma SNPs on CpGs from the EWAS of asthma at
7.5 years adjusted for basic cell counts.
For assessing the causal effects of asthma on DNA
methylation, asthma SNPs from the GWAS catalogue
[58] were used as IVs for asthma and methylation
data from the ARIES dataset was used as our second
sample (Additional file 1: Figure S2). Specifics on the
selection and QC of SNPs from the GWAS catalogue
used as IVs can be found in Additional file 1. A com-
bination of methods, including the inverse variance-
weighted method, maximum likelihood method,
weighted median method and MR-Egger regression,
were used as sensitivity analyses. We tested for plei-
otropy by assessing the MR-Egger regression intercept
with funnel plots/scatter plots and for heterogeneity
using Cochran’s Q statistic.
In the reverse direction, cis-SNPs robustly associ-
ated with methylation levels at the specific CpG sites
were used as proxy IVs for DNA methylation. For
assessing the causal effect of DNA methylation on
asthma, we identified cis-SNPs associated with EWAS
hits in ARIES [59] and assessed the association of
these cis-SNPs with asthma using summary data from
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the GABRIEL consortium GWAS of asthma [6] as
the second sample (Additional file 1: Figure S3). The
Wald ratio method was used in the DNA methyla-
tion to asthma direction as only one cis-SNP was se-
lected per CpG due to high linkage disequilibrium
(LD) between neighbouring SNPs.
We calculated the effective number of independent tests
for both the asthma to methylation and the methylation
directions of the MR analysis. Adjustment for multiple
testing is required when large numbers of tests are per-
formed in an MR framework. However, CpGs are likely to
be co-methylated if they are located in the same gene or
close to each other on the chromosome. In order to take
into account potential correlation between nearby CpGs,
we calculated the effective number of independent tests
for the 302 CpGs using matSpDlite [60]. Briefly, the
method determines the number of independent tests
using spectral decomposition of the correlation matrix of
the tested exposures or outcomes. It calculates the equiva-
lent number of independent variables in the correlation
matrix by examining the ratio of observed eigenvalue vari-
ance to its theoretical maximum. The method calculates a
P value at which type 1 errors are kept at 5% based on the
Veff process described by Li and Ji [61].
We performed power calculations using the mRnd
Mendelian randomization power calculator by CNS gen-
omics available online [62]. In the asthma to DNA methy-
lation direction, we had a maximum 6% power to detect a
3% change in methylation. In the DNA methylation to
asthma direction, we had a maximum 73% power to de-
tect an OR of 1.1. Details of the power calculation can be
found in Additional file 1. Due to the low power to detect
causal effects using Mendelian randomization, we present
results for all CpGs from the EWAS and discuss in detail
results from the top 20 CpGs based on lowest P value in
the EWAS only, as they demonstrate the most robust
association with asthma status. Specific details of the MR
process can be found in Additional file 1.
Results
Sample characteristics
Descriptive statistics of ARIES individuals included in
each EWAS model are shown in Table 1. Individuals in-
cluded as cases in each model were more likely to have a
mother that smoked when compared to controls. There-
fore, we adjusted for maternal smoking in all models as
well as other potential confounders (maternal education,
parity and maternal age).
There was strong evidence of associations between
current asthma and estimated cell counts, particularly in
childhood (Table 2). Current asthma at 7.5 years demon-
strated a strong positive association with estimates of B
cells and eosinophils, with a 0.026 [95%CI 0.018, 0.033]
increase in the proportion of B cells and a 0.011 [95%CI
0.005, 0.018] increase in the proportion of eosinophils in
individuals with asthma respectively. There was a strong
negative association with current asthma at the same
age for neutrophils, with a 0.042 [95%CI − 0.06, − 0.022]
decrease in proportion of neutrophils in individuals with
asthma. However, granulocytes (summed proportion of
eosinophils and neutrophils) were not associated with
current asthma at the same age. Similarly, current
asthma at 16.5 years demonstrated a positive association
with estimates of derived eosinophils at 16.5 years with a
0.005 [95%CI 0.002, 0.008] increase in proportion, al-
though with markedly less confidence in the estimate
than the associations at 7.5 years. There was no evidence
of an association between asthma at either 7.5 or
16.5 years and any of the other cell types. A graphical
depiction of the distributions of cell counts by asthma sta-
tus at both 7.5 and 16.5 years is shown in Fig. 1. The same
association with eosinophil cell counts was present for
current wheeze at 7.5 years (Additional file 1: Figure S4).
Associations of asthma at 7.5 years with cell counts
stratified by atopic status indicate that increased eosino-
phils were evident in both atopic and non-atopic individ-
uals with asthma. There was a 0.032 [95%CI 0.016, 0.047]














[O-level or lower] N (%)
7.5 years Current asthma
at 7.5 years
Cases 149 88 (59%) 369 (53.4) 124 (83%) 62 (42%) 68 (46%)
Controls 632 308 (49%) 364 (51.7) 560 (89%) 286 (45%) 306 (48%)
Current wheeze
at 7.5 years
Cases 111 66 (60%) 372 (55) 94 (85%) 43 (39%) 520 (45%)
Controls 742 366 (49%) 361 (52) 650 (88%) 348 (47%) 362 (49%)
16.5 years Ever asthma
at 16.5 years
Cases 194 102 (53%) 363 (53) 163 (84%) 97 (50%) 87 (45%)
Controls 554 264 (48%) 364 (51) 503 (91%) 258 (47%) 262 (47%)
Ever wheeze
at 16.5 years
Cases 204 108 (53%) 367 (49) 173 (85%) 102 (50%) 82 (40%)
Controls 554 264 (48%) 363 (52) 503 (91%) 261 (47%) 271 (49%)
Current asthma
at 16.5 years
Cases 184 73 (40%) 362 (51.6) 150 (82%) 89 (48%) 89 (46%)
Controls 427 200 (47%) 364 (51.7) 384 (90%) 204 (48%) 198 (46%)
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difference in the proportion of eosinophils in atopic indi-
viduals with asthma (Additional file 1: Table S4), whereas
for non-atopic individuals with asthma, the association
was somewhat weaker with a 0.016 [95%CI 0.007, 0.025]
difference in the portion of eosinophils. For non-atopic in-
dividuals, there was also evidence of an association of
asthma with B cells and neutrophils, with a 0.015 [95%CI
0.007, 0.023] and − 0.039 [95% CI − 0.065, − 0.014] differ-
ence in proportion respectively.
Epigenome-wide association analyses
We identified 411 CpG sites associated with current
asthma status at 7.5 years (FDR-adjusted P value < 0.05)
and 611 CpG sites with current wheeze status at
7.5 years. When adjusted for cell counts (eosinophils
and neutrophils grouped together as granulocytes), 302
CpG sites remained associated with current asthma and
445 with current wheeze at 7.5 years. Adjusting for cell
counts that included neutrophil and eosinophil counts
separately (detailed cell counts) attenuated all associa-
tions (Table 3). We found evidence of genomic inflation
in all unadjusted models that reduced progressively once
adjustments for basic cell counts and detailed cell counts
were made (Additional file 1: Figure S6). As expected,
we found strong associations between DNA methylation
and estimated eosinophil cell counts at CpGs associated
with current asthma at 7.5 years (Additional file 2:
Tables E23 and E24). The top locus associated with
current asthma at 7.5 years adjusted for cell counts that
did not include eosinophils and neutrophils mapped to
ZFPM1 (cg04983687) with a − 5.02 [95% CI − 3.5, − 6.5]
difference in percentage methylation for individuals with
asthma. A larger number of sites were associated with
current wheeze at age 7.5 years (445 CpG sites), and the
top locus mapped to MFHAS1 (cg1207746) with a − 4.60
[95%CI − 3.33, − 5.86] difference in percentage methyla-
tion for individuals with wheeze. There was a high
degree of overlap between current asthma- and current
wheeze-associated CpG sites (57.1% of 611 sites associ-
ated with current wheeze or 349 CpG sites) in the un-
adjusted model (55.7% of 445 sites associated with
current wheeze or 248 CpG sites in the adjusted model).
Current asthma at 16.5 years was associated with 2
CpGs in the unadjusted model that persisted after ad-
justment for both basic cells and for detailed cells that
included eosinophils and neutrophils. The CpGs were
annotated to the genes AP2A2 (cg17676835) and IL5RA
(cg10159529) with a − 2.3 [95% CI − 1.47, − 3.18] differ-
ence and − 2.5 [95% CI − 1.56, −3.43] difference in per-
centage methylation, respectively, in the model adjusted
for eosinophils and neutrophils (Fig. 2). There were no
associations observed between methylation at 16.5 years
and ever asthma status at the same age. There were 32
CpGs associated with ever wheeze at 16.5 years once ad-
justed for basic cells, but all associations attenuated once
adjusted for cell counts that included eosinophils and
neutrophils. Full results for all probes with a P value <
1e-3 can be found in Additional file 2: Tables E1–E15.
In the longitudinal EWAS models, we identified 4
CpGs where DNA methylation at 7.5 years was associ-
ated with asthma at 16.5 years (FDR < 0.05). When ad-
justed for cell counts that included eosinophils and
neutrophils, all associations attenuated. In the model un-
adjusted for cell counts, the top hit mapped to the IRGC
gene. We identified 28 CpGs where DNA methylation at
16.5 years was associated with asthma at 7.5 years. Fol-
lowing adjustment for detailed cell counts, all associa-
tions attenuated. In the unadjusted model, the top hit
mapped to the MACROD1 gene. We observed high
inflation in all models that reduced only marginally with
adjustment for estimated cell counts (Table 4 and
Additional file 1: Figure S7). Full results for all probes
with a P value < 1e-3 can be found in Additional file 3:
Tables F1–F6.
Table 2 Associations of estimated cell counts at 7.5 and 16.5 years with current asthma status at 7.5 and 16.5 years respectively
Current asthma at 7.5 years Current asthma at 16.5 years
Change in proportiona [95%CI] P value Change in proportiona [95%CI] P value
Monocytes − 0.002 [− 0.005, 0.004] 0.695 − 0.003 [− 0.007, 0.004] 0.534
CD8T 0.002 [− 0.008, 0.009] 0.777 − 0.004 [− 0.013, 0.007] 0.496
CD4T 0.009 [− 0.002, 0.018] 0.069 0.009 [0, 0.018] 0.055
B cells 0.011 [0.005, 0.018] < 0.001 0.005 [− 0.003,0.01] 0.173
NK cells − 0.004 [− 0.008, 0.002] 0.159 − 0.004 [− 0.01,0.004] 0.306
Granulocytesb − 0.016 [− 0.032, 0.001] 0.065 − 0.005 [− 0.023, 0.014] 0.618
Neutrophils − 0.042 [− 0.06, − 0.022] < 0.001 − 0.009 [− 0.029, 0.011] 0.382
Eosinophils 0.026 [0.018, 0.033] < 0.001 0.005 [0.002, 0.008] 0.008
aChange in proportion for individuals with asthma
bGranulocytes calculated from the summed proportions of eosinophils and neutrophils
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Sensitivity analyses
In order to check whether associations of current
asthma status at 7.5 years and cell counts were driven by
outlier individuals with extreme levels of eosinophil cell
counts, two outlier removal methods (Tukey’s method of
outlier removal [47], both stringent and relaxed) were
applied to the eosinophil cell count data. Additional file 1:
Table S5 shows the effect of removal of outliers from the
eosinophil cell counts. The association of asthma status
with eosinophil cell counts remains even after stringent
outlier removal. However, stratifying by sex shows that
this appears to be a male phenomenon since there is no
observed association in females (P > 0.05), as shown in
Additional file 1: Table S6. The persistent association ap-
pears to be driven almost entirely by males. Based on
this observation, we conducted a sensitivity analysis
where we restricted the EWAS sample to just females
for current asthma at 7.5 years (N = 385). There was one
site associated with current asthma in the model un-
adjusted for cell counts (cg07612991); however, once ad-
justed for basic cell counts, the association attenuated
(Additional file 2: Tables E16, E17 and E18). Power to
detect an effect may have been greatly reduced in the
model due to halving of the original sample size.
Fig. 1 Box plots of the estimated proportions of the different cell types. Comparison between individuals with asthma and individuals with no
asthma. a Estimated cell counts at 7.5 years of age by current asthma status at 7.5 years and b estimated cell counts at 16.5 years of age by
current asthma status at 16.5 years. Granulocytes calculated from the summed proportions of eosinophils and neutrophils
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In order to ensure that adjustment for all 7 estimated
cell counts was not having unintended effects due to
multicollinearity between the estimates, we ran the same
EWAS of current asthma at 7.5 years adjusted only for
estimated eosinophils. However, we observed the same
attenuation of associations as the model adjusted for all
7 estimated cell counts.
Enrichment analysis/functional analysis/gene ontology
A look up in the GO [51] and KEGG [53] databases
showed that the 192 genes annotated to the 302 hit
CpGs from the EWAS of current asthma at 7.5 years
adjusted for basic cells were located in pathways related
to movement of cellular or subcellular components,
locomotion, interleukin-4 production and eosinophil mi-
gration. The genes were enriched in the following KEGG
pathways: amino/nucleotide sugar metabolism and
asthma (Additional file 1: Tables S7 and S8).
Mendelian randomization
Asthma to DNA methylation
We found some evidence of a causal effect of asthma on
DNA methylation at several CpG sites (Additional file 2:
Table E19). One CpG was among the top 20 hits from the
Table 3 Results of epigenome-wide association studies (EWAS), where methylation is the outcome and current asthma at 7.5 years,
current wheeze at 7.5 years, current asthma at 16.5 years, ever asthma at 16.5 years and ever wheeze at 16.5 years are the exposures
Methylation (outcome) Asthma/wheeze (exposure) N [cases/controls] Cell adjustment FDR hits [Bonferroni] Lambda
7.5 years Current asthma at 7.5 years 781 [149/632] No cells 411 [67] 1.08
Basic cells 302 [43] 1.01
Detailed cells 0 [0] 0.97
Wheeze at 7.5 years 853 [111/742] No cells 611 [105] 1.14
Basic cells 445 [78] 1.08
Detailed cells 0 [0] 1.00
16.5 years Ever asthma at 16.5 years 748 [194/554] No cells 0 [0] 1.09
Basic cells 0 [0] 1.05
Detailed cells 0 [0] 1.01
Ever wheeze at 16.5 years 758 [204/554] No cells 48 [9] 1.02
Basic cells 32 [9] 1.05
Detailed cells 0 [0] 1.01
Current asthma at 16.5 years 611 [184/427] No cells 2 [2] 1.01
Basic cells 2 [2] 1.05
Detailed cells 2 [1] 0.99
All models are adjusted for confounders and technical covariates. Stepwise adjustments for estimated cell counts were made (where basic cells include
CD8T, CD4T, NK, monocytes, B cells and granulocytes and detailed cells include eosinophils and neutrophils instead of granulocytes)
FDR-adjusted P value and Bonferroni hits use a cut-off of < 0.05. Lambda based on P values of all probes without exclusions
Fig. 2 Manhattan plot of current asthma at 16.5 years adjusted for detailed cells. FDR significance cut-off line in green and Bonferroni cut-off line in red
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EWAS of current asthma at 7.5 years, cg12077460 anno-
tated to geneMFHAS1 with − 0.022 difference in methyla-
tion in asthma cases (P = 0.013) shown in Fig. 3. However,
none of the causal effect estimates met the calculated sig-
nificance threshold of P = 3.4 × 10−4 calculated based on
the number of effective independent tests (n = 151).
In the two CpG sites associated with asthma at
16.5 years, there was no evidence of a causal effect of
asthma on DNA methylation, at either the AP2A2 gene
(cg17676835) or IL5RA (cg10159529) shown in
Additional file 2: Table E21.
DNA methylation to asthma
In the reverse direction, from DNA methylation to
asthma, 31 out of 302 CpGs were found to have cis-SNPs
that were available in the meta-analysis results of the
GABRIEL asthma GWAS. We were therefore only able to
test the causal association at these 31 CpGs. There was
evidence for a causal association between one CpG
(cg11938718) and asthma annotated to the HPCAL1 gene
with a 0.0177 change in log odds of asthma per 1%
increase in methylation (P = 2.5 × 10−3) shown in
Additional file 2: Table E22. The strength of the effect did
not meet the significance threshold calculated based on
the number of independent tests (n = 21, adjusted P =
2.4 × 10−3). The effect of the CpG on asthma was in the
same direction as the observational effect from the EWAS
(shown in Additional file 2: Table E2).
Neither of the two CpG sites associated with asthma
at 16.5 years had available cis-SNPs that could be used
as IVs. We were therefore unable to test the causal asso-
ciation in the reverse direction.
Discussion
We have found multiple differentially methylated CpG
sites in peripheral blood of asthmatics compared to that of
non-asthmatics in childhood. However, adjustment for eo-
sinophils and neutrophils attenuated all associations in
childhood. This is in line with our expectations of eosino-
phils being the driving factor in the detected signals. Eo-
sinophilic inflammation is considered a characteristic of
allergic asthma [27, 63], which is more common in child-
hood than adulthood. As expected, we find a far weaker
association of asthma at 16.5 years with eosinophil cell
counts, as adult onset asthma is more often non-atopic,
with eosinophilic asthma representing a rarer and more
severe endotype of asthma at that age [16]. Differences in
the number of CpGs associated with asthma in childhood
(at 7.5 years) compared to adolescence (at 16.5 years) are
most likely a reflection of the differences in prevalence of
allergic asthma between childhood and adolescence. Over-
all, we found markedly fewer associations at 16.5 years
than at 7.5 years with respect to current asthma and ad-
justments for cell counts at 16.5 years of age did not have
the same impact as adjustments at 7.5 years, which is con-
sistent with our hypothesis that eosinophil confounding in
adolescence has weaker effects than in childhood. Overall,
these observations are consistent with the likelihood that
childhood asthma does not affect DNA methylation dir-
ectly in our sample but does affect estimates of DNA
methylation from a mixed cell population due to the asso-
ciation between asthma and the constitution of the cell
population.
We found more associations between current wheeze
and DNA methylation at 7.5 years (611 hit CpG sites)
than for current asthma (411 hit CpG sites) at the same
age. However, we observed the same attenuation in effects
when adjusting for cell counts that include eosinophils in
the current wheeze model. In the unadjusted model of
current wheeze, the CpG site with the strong association
(cg12077460) mapped to the MFHAS1 gene, whereas the
top association in current asthma mapped to ZFPM1
(cg04983687). Asthma medications are known to reduce
eosinophils in the blood [64], and study participants that
report current wheeze may be more likely to be untreated
asthma cases than those reporting doctors’ diagnosis of
asthma. Therefore, current wheeze cases may have a mar-
ginally higher proportion of eosinophils than those de-
fined as current asthma which explains the higher number
of associations in the wheeze model that attenuate upon
adjustments for estimated eosinophils.
In the EWAS of current asthma at 16.5 years, the two
CpGs that remained significant after adjustment for de-
tailed cells mapped to the AP2A2 and IL5RA genes. In
the EWAS of current asthma at 7.5 years, cg17676835
(AP2A2) was not associated with current asthma at
Table 4 Results of the longitudinal epigenome-wide association studies (EWAS)
DNA methylation Asthma definition N [cases/controls] Cell adjustment FDR hits [Bonferroni] Lambda
7.5 years Current asthma at 16.5 years 611 [182/429] No cells 4 [2] 1.11
Basic cells 9 [2] 1.13
Detailed cells 0 [0] 1.10
16.5 years Current asthma at 7.5 years 784 [146/638] No cells 28 [0] 1.24
Basic cells 1 [1] 1.16
Detailed cells 0 [0] 1.14
FDR-adjusted P value and Bonferroni hits use a cut-off of < 0.05
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7.5 years when adjusted for granulocytes only (basic
cells), whereas cg10159529 (IL5RA) was strongly associ-
ated in the same direction (P = 0.0001) but attenuated
when adjusted for cell counts that included eosinophils
and neutrophils (P = 0.304).
In the longitudinal EWAS, we observed similar attenu-
ation of all associations to the cross-sectional models
once adjustments for eosinophils and neutrophils were
made. Inflation persisted even after adjustments, indicat-
ing residual confounding or unaccounted for variation.
Notably, cg04983687 in the ZFPM1 gene, which was the
top hit in the cross-sectional model of current asthma at
7.5 years, remained nominally associated in both longi-
tudinal models (P = 0.008 for current asthma at 7.5 years
and methylation in adolescence, and P = 0.01 for current
asthma at 16.5 years and methylation childhood) with
the same direction of effect. Several other CpGs from
the top 20 hits in the cross-sectional model of current
asthma at 7.5 years, such as cg20673965 (IRGC) and
cg19805160 (CCDC19), also demonstrated consistent
Fig. 3 Causal effect of asthma on DNA methylation. Estimated effects at each of top 20 CpGs from EWAS of asthma at 7.5 years and methylation
at 7.5 years using two-sample Mendelian randomization approach. Obs observational effect from EWAS, IVW inverse variance-weighted,
ML maximum likelihood, WM weighted median, MR-Egger MR-Egger regression
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direction of effect in both of the longitudinal models
despite only weak evidence of an association.
In sensitivity analysis of the sex-stratified EWAS
models, we did not identify any single site associated
with current asthma at 7.5 years in females indicating
that the strong confounding effect seen in the mixed sex
EWAS appears to be driven by differences in eosinophils
mostly in males. This observation fits with the results of
the sex-stratified associations of cell counts and asthma
that showed that the strongest association of eosinophils
and asthma was in the male subgroup. Several differen-
tially methylated CpG sites in the EWAS of current
asthma at 7.5 years were located in genes that have
known links to both eosinophil functions and allergic
sensitisation, such as cg27469152 in the 3′UTR region
of the EPX gene. The gene encodes eosinophil peroxid-
ase, an enzyme expressed in eosinophils [65] and re-
leased at sites of parasitic infection or allergic
stimulation [66, 67]. Both current asthma at 16.5 years
and ever wheeze at 16.5 years were negatively associated
with methylation levels at IL5RA, a gene encoding alpha
subunit of the interleukin-5 (IL5) receptor. Decreased
expression of IL5 membrane receptor on eosinophils has
been previously linked to allergen stimulation and in-
creased IL5 protein levels in the airways [68].The fact
that the association remains significant after adjustment
for detailed cell counts in the model of current asthma
at 16.5 years may indicate incomplete adjustment for eo-
sinophils. Genetic polymorphisms of the AP2A2 gene
have also previously found to be associated with bron-
chitis and chronic obstructive pulmonary disease
(COPD) [69].
Cell type heterogeneity
The increase of eosinophils in some individuals with
asthma presents challenges when assessing whole blood
DNA methylation [29, 30], as the distinct methylation
patterns of eosinophils [31] are over-represented in
cases. Correction for white blood cell heterogeneity can
be implemented; however, doing so adjusts for known
characteristics of the disease outcome (asthma), there-
fore making it difficult to decipher methylation-related
differences that are truly linked to the disease outcome.
Adjusting for cell type heterogeneity that may exist be-
tween different samples in an EWAS is of critical im-
portance [29] and multiple different methods have been
devised to address the issue, which may be considered as
a form of confounding [70], although this categorisation
is dependent on the hypothesis being tested. However,
when a specific cell type forms an intermediate pheno-
type with involvement in the pathogenesis and charac-
teristic features of a disease, then the unadjusted signals
may be of biological interest. Raised eosinophil levels
have been suggested to be an intermediate phenotype or
feature of asthma [71]. In the case of asthma, detected
CpG signal from eosinophils may tag potentially patho-
genic genes that might be causal to the asthma pheno-
type, when expressed differentially in blood due to
higher numbers of eosinophils. By adjusting for esti-
mated eosinophil counts, that signal is attenuated but
may still have biological relevance.
Causal analyses
Methods of causal inference such as MR help to define
direction of causation in detected associations. Our MR
analysis suggested a causal effect of asthma on DNA
methylation at several CpG sites associated with asthma
at 7.5 years. However, none of the effects survived mul-
tiple testing, even after adjusting the P value threshold
to take into account correlation between the outcomes.
Similarly, in the reverse direction, from DNA methyla-
tion to asthma, there was no robust evidence for causal
effects. When compared to the observational effects
from the EWAS, estimates from the MR analysis were
weaker, but with consistent direction of effect to the ob-
servational evidence. The fact that effect estimates from
the MR were so weak in comparison to estimates from
the EWAS further confirms lack of power in the MR
analysis, as indicated by our power calculation. We used
a combination of complementary methods to ascertain
these causal effects in MR, including the fixed effect
meta-analysis of Wald ratios, the inverse variance-
weighted (IVW) method and the MR-Egger regression.
The two-sample MR analysis was underpowered due to
small sample size used to determine the SNP methyla-
tion association, comprising just over 1000 individuals
(from the ARIES-ALSPAC sample), and we were not
able to determine causality in either direction. Future
work should aim to increase power by increasing the
sample size in the dataset.
Based on these results, we also attempted a two-
sample MR analysis of eosinophils and DNA methyla-
tion using previously published SNPs that have shown
strong association with eosinophil cell counts in periph-
eral blood [72]. However, the derived IVs from the pub-
lished GWAS results were too weak to detect an effect
in our sample. Future studies may identify further se-
quence variants that associate with eosinophil counts
and provide more powerful IVs for MR analysis.
The genetic instruments used in the asthma to DNA
methylation direction of the MR analysis were relatively
weak in comparison to other IVs used in previous MR
studies. Asthma GWAS from which the IVs were
sourced have identified SNPs that explain very little of
the population variance in asthma in comparison to
other traits [6, 73]. Furthermore, our strict LD R2 cut-off
threshold of < 0.1 reduced the total amount of SNPs
used as IVs to just six. In the reverse direction, from
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DNA methylation to asthma, we included only one cis-
SNP for each CpG tested since strong LD was observed
between neighbouring SNPs that forced the exclusion of
many cis-SNPs that would have otherwise been com-
bined to form stronger IVs.
Comparisons with previous literature
A previously published EWAS of total serum immuno-
globulin E (IgE) identified 36 CpG sites associated with
differential levels of IgE [21]. IgE is a marker of allergic
asthma and, as such, would be expected to be implicated
in the biological pathway leading to allergic or inflamma-
tory disease [74]. Whereas IgE is a robust biomarker of in-
flammatory conditions, it may not accurately proxy
asthma as it encompasses a wide variety of atopic or in-
flammatory conditions. Of the 36 identified CpGs in this
previous study, 35 were analysed in our EWAS, with 15
associated with current asthma at 7.5 years (FDR < 0.05),
and 13 remaining associated after adjustment for basic
cells (FDR < 0.05). Comparisons of results can be seen in
Additional file 1: Table S11. This corroboration of findings
suggests that eosinophil specific methylation patterns may
be directly involved in asthma pathogenesis via raised IgE.
A recent EWAS of IgE in Hispanic children [22] re-
ported associations with DNA methylation in CpGs an-
notated to the ZFPM1 (cg04983687, cg08940169) and
ACOT7 (cg09249800, cg21220721, cg11699125) genes.
We observe similar strong associations with CpG sites
annotated to the same genes in the unadjusted EWAS of
current asthma at 7.5 years (Additional file 2: Tables E1
and E2). However, these associations attenuate following
adjustment for eosinophils and neutrophils, unlike the
previously reported results. Furthermore, we have ex-
cluded all CpGs except cg04983687 (ZFPM1) from the
results of our analyses as they have previously been indi-
cated to be low-quality probes due to the effects of re-
peats, SNPs, INDELs and reduced genome complexity
[46]. Differences between results may indicate residual
confounding due to eosinophils in previous results or
lack of power in our own analyses, due to a lower num-
ber of asthma cases compared to controls relative to the
previous study. Additionally, we have used exclusively
methylation-estimated cell counts to adjust for cell mix-
ture as opposed to cell sorted estimates of the previous
study, leading to potentially imprecise adjustments in
our own analyses. In a sensitivity analysis, we generated
estimated cell counts using the Houseman algorithm
[41] and the 200 reference CpGs supplied in the supple-
mentary material of the previous study [22]. Correlations
between the estimated cell counts using the estimated
reference CpGs and our own Houseman-derived esti-
mates were relatively low. For eosinophils, the correl-
ation was 0.77, for neutrophils 0.96, for NK cells 0.57,
for CD4T cells 0.75, for B cells 0.71, for CD8T cells 0.13
and for monocytes 0.76. As a sensitivity analysis using
these estimated cell counts we reran the EWAS of
asthma at 7.5 years; however, there were no associations
between DNA methylation and asthma (FDR < 0.05).
A previously published EWAS of asthma performed in
peripheral blood mononuclear cells (PBMCs) found
similar associations to our own unadjusted results [23].
The EWAS focused on children with atopic asthma liv-
ing in the inner city with an African-American, Hispanic
or Caribbean background. The study identified differen-
tially methylated regions (DMRs) as opposed to single
sites, with many of the resulting associations mapping to
genes such as ACOT7 and IL13 that were also identified
in our own unadjusted analyses. The study used the
same algorithm to estimate cell counts; however, EWAS
models were only adjusted for residual granulocyte con-
tamination and not eosinophils and neutrophils separ-
ately, since the study used PBMC samples (which
exclude granulocytes). Differences in samples (PBMCs vs
whole blood) make it difficult to compare the study’s re-
sults to our own findings. As is evident from our ana-
lyses, adjusting for granulocytes alone does not appear
to be sufficient for countering the confounding effects of
eosinophils in EWAS using whole blood; however,
EWAS based on DNA methylation from PBMC samples
may be less affected by cell-type differences. Similarly, a
study of asthma using methylation data from nasal epi-
thelium observed associations between asthma and
DNA methylation but did not specifically adjust for eo-
sinophil cell counts [24]. However, the authors in this
study did attempt to perform cell sorting which may
have negated some of the confounding effects of cell
mixtures by ensuring a more homogenous cell sample
enriched for epithelial cells. We therefore cannot con-
clude if confounding by eosinophils affects their results.
The authors of both of these studies however do not ap-
pear to have discussed confounding effects of differences
in eosinophils per se between study cases and controls.
Strengths and limitations
Strengths of the study include the ability to compare
two different time points in the same cohort of individ-
uals, with methylation from childhood and adolescence,
forming a series of cross-sectional and longitudinal ana-
lyses. Our use of complementary approaches to answer-
ing each question, which includes the functional
analysis, sensitivity analyses and bi-directional MR (with
multiple different testing methods applied), gives greater
strength to our conclusions.
Limitations include the low coverage of the Human-
Methylation450 Beadchip array, including less than
2% of all CpG sites [75]. Combined with our various
probe exclusions, this brings the overall coverage
down to just a fraction of the full methylome. Our
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analyses rely on the use of methylation data generated
from peripheral blood leukocytes (PBLs), which may
not be the most appropriate tissue in which to study
associations with asthma. Cells from other tissues
may be more relevant, such as airway epithelial cells,
buccal cells or cells from bronchoalveolar lavage. In
addition, our cell counts are estimated from the
methylation data using a reference dataset instead of
being directly sorted and counted in the original
blood samples. Whereas the method has been previ-
ously validated [76] and previous EWAS analyses have
found strong correlations between estimated and cell
sorted measures [22], it may not perform well in predict-
ing proportions of rarer cell types in the blood, such as eo-
sinophils, as they may be subject to less favourable signal-
to-noise ratios than high abundance cell types. However,
we attempted to counter the potentially poor estimation
of cell counts by using surrogate variables in our EWAS
analysis, a reference-free method of adjusting for un-
known confounding factors. We did not assess to what ex-
tent our detected associations were explained by genetic
variants, such as SNPs.
Measurement error due to misreporting of asthma
diagnosis is another limitation. Since our outcomes
are derived from self-report questionnaires from ei-
ther the mothers of the study children or the study
children themselves, they are subject to misreporting
of symptoms or previous asthma diagnosis. Any mis-
reporting of asthma/wheeze symptoms is likely to bias
results towards the null. However, a validation study
linking childhood asthma self-reports in ALSPAC
using linked electronic patient records from GP prac-
tices shows that parental reports of a doctor’s diagno-
sis agree well with GP-recorded diagnosis [77]. The
Mendelian randomization is robust to measurement
error in the exposure due to the use of genetic vari-
ants but may be subject to other biases in exposure
and outcome [78].
Finally, whereas we were able to perform the analyses
in a large well-phenotyped birth cohort, we were limited
by the number of individuals with available DNA methy-
lation data at each time point and analyses may have
been underpowered to detect small effects in the pres-
ence of strong confounding by cell type. Future studies
should aim to increase sample size by meta-analysis in
order to ensure adequate power to detect effects, over-
coming the confounding effects of differential cell
counts between asthma cases and controls.
Conclusion
We have shown multiple significant associations between
asthma status and peripheral blood DNA methylation in
both childhood and adolescence. There is strong evidence
to suggest that the observed associations are driven to a
large extent by higher eosinophil counts in asthmatics in
childhood. We have shown that the use of whole-blood
450 K data in EWAS of allergic diseases, such as asthma,
where eosinophils may be expected to play a contaminat-
ing or confounding role in disease cases, makes it difficult
to disentangle true associations of the disease with methy-
lation from associations that may be driven by the over-
representation of eosinophils. Whereas further work is
needed to devise methods of elucidating true associations
from those that are due to cell type confounding, this does
not fully preclude the biological relevance of the observed
differential methylation as raised eosinophils are a con-
stituent part of the asthma phenotype.
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